Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …
Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion
P Dong, Y Xiong, J Yue, SJB Hanley, H Watari - Frontiers in oncology, 2018 - frontiersin.org
Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively
documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in …
documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in …
KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment
P Dias Carvalho, CF Guimaraes, AP Cardoso… - Cancer research, 2018 - AACR
KRAS is one of the most frequently mutated oncogenes in cancer, being a potent initiator of
tumorigenesis, a strong inductor of malignancy, and a predictive biomarker of response to …
tumorigenesis, a strong inductor of malignancy, and a predictive biomarker of response to …
[HTML][HTML] Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations
Introduction Programmed death 1/programmed death ligand 1 (PD-L1) axis inhibitors have
been proven effective, especially in patients with tumors expressing PD-L1. Their clinical …
been proven effective, especially in patients with tumors expressing PD-L1. Their clinical …
Heterogeneity of PD-L1 expression and relationship with biology of NSCLC
M Bassanelli, S Sioletic, M Martini, S Giacinti… - Anticancer …, 2018 - ar.iiarjournals.org
Immunotherapy with monoclonal antibodies against programmed cell death (PD-1), such as
nivolumab and pembrolizumab, has significantly improved the survival of patients with …
nivolumab and pembrolizumab, has significantly improved the survival of patients with …
PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma
Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of thyroid cancer that
currently has limited effective treatment options. Immune checkpoint inhibitors (ICIs) have …
currently has limited effective treatment options. Immune checkpoint inhibitors (ICIs) have …
Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma …
AT Falk, N Yazbeck, N Guibert, E Chamorey, A Paquet… - Lung Cancer, 2018 - Elsevier
Objectives The effect of anti-PD-1/PD-L1 inhibitors on lung adenocarcinomas (LADCs) with
KRAS mutations is debatable. We examined the association between specific mutant KRAS …
KRAS mutations is debatable. We examined the association between specific mutant KRAS …
E3 ubiquitin ligases Cbl‐b and c‐Cbl downregulate PD‐L1 in EGFR wild‐type non‐small cell lung cancer
S Wang, L Xu, X Che, C Li, L Xu, K Hou, Y Fan… - FEBS …, 2018 - Wiley Online Library
Anti‐PD‐1/PD‐L1 therapies have demonstrated prominent clinical effects in the treatment of
non‐small cell lung cancer (NSCLC). However, limited understanding of the regulatory …
non‐small cell lung cancer (NSCLC). However, limited understanding of the regulatory …
Extracellular matrix functions in lung cancer
M Götte, I Kovalszky - Matrix Biology, 2018 - Elsevier
Lung cancer is one of the most devastating types of malignant tumors, and a prime example
of a chemical carcinogenesis-driven tumor entity. Lung cancer progression does not only …
of a chemical carcinogenesis-driven tumor entity. Lung cancer progression does not only …